Lipocine INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
LPCN
Lipocine INCLipocine Inc. has filed its proxy statement for the 2026 Annual Meeting of Stockholders to be held on June 3, 2026.
NASDAQ
LPCN
Lipocine INCDEF: Lipocine Inc. Announces 2025 Annual Meeting of Stockholders, Proposes Share Authorization Decrease
Lipocine Inc. is set to hold its 2025 Annual Meeting of Stockholders on June 4, 2025, featuring proposals including the election of directors, ratification of the accounting firm, an advisory vote on executive compensation, and a significant decrease in authorized common stock shares.
NASDAQ
LPCN
Lipocine INCLipocine Inc. amends its 2014 Stock and Incentive Plan to increase the authorized number of shares and prohibit option repricing without stockholder approval, seeking ratification at the upcoming annual meeting.
NASDAQ
LPCN
Lipocine INCLipocine Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to address key proposals including the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the stock and incentive plan.